Ramy Sedhom, Director of Medical Oncology and Palliative Care at Penn Medicine Princeton Health, shared a post on X about a paper by Veronica Mears et al. published in JCO Oncology Practice:

“Credit to JCO Oncology Practice for publishing this study.

Small, single-institution experience but likely informative of our collective experience

<50% of patients completed all planned CapeOX cycles
~30% experience grade III or greater AEs
~18% hospitalized during treatment.

What can we learn from this work?

‘real world’ experiences differ from trials
how we frame Rx matters

Patients are scared of recurrence, and yet chemo is hard to tolerate. Always good to remind patients dose-reductions, dose-interruptions, and early discontinuation happens

Note: few older adults were represented in this cohort, and I’m sure data toxicity rates would be even higher at many centers in the community.”

“Real-World Tolerability of Capecitabine and Oxaliplatin in Patients in the United States With Localized Colorectal Cancer Undergoing Curative-Intent Treatment”

Authors: Veronica Mears, Nikolas Naleid, Omkar Pawar, Jennifer Selfridge, Madison Conces, Melissa Lumish, David Bajor, Amit Mahipal, Sakti Chakrabarti.

Ramy Sedhom: Real-world challenges in CapeOX tolerability for localized colorectal cancer